Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies
Worldwide Clinical Trials
MAY 30, 2024
Approval has been based on bioequivalence with the FDA stating that the effectiveness of Radicava ORS is based on a study showing comparable levels of Radicava ORS in the bloodstream to the levels from the IV formulation of Radicava. This is administered according to the same treatment regimen as for the IV infusion.
Let's personalize your content